[Treatment of malignant lymphomas with shock doses of peptichemio].
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D001773:Blood Cells / Q000187:drug effects; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008099:Liver / Q000187:drug effects; D008223:Lymphoma / Q000188:drug therapy*; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010455:Peptides; D001761:Bleomycin; D014750:Vincristine; D011241:Prednisone; D008727:Methotrexate
Trattamento dei linfomi maligni con dosi urto di peptichemio